Large-Scale Clinical Expansion of Mesenchymal Stem Cells in the GMP-Compliant, Closed Automated Quantum® Cell Expansion System: Comparison with Expansion in Traditional T-Flasks

Chantal Lechanteur1*, Stefano Baila2, Michiel Etienne Janssens3, Olivier Giet4, Alexandra Briquet4, Etienne Baudoux4 and Yves Beguin1,3

1Laboratory of Cell and Gene Therapy, CHU of Liège and University of Liège, Liège, Belgium
2Terumo BCT, Lakewood, Colorado, USA
3Department of Medicine, Division of Hematology, University of Liège, Liège, Belgium

Abstract

Objectives: Significant advances have been achieved regarding the knowledge of the immunoregulatory properties of mesenchymal stem cells (MSC). We are currently involved in several clinical protocols evaluating these properties in different settings including hematopoietic cells or solid organ transplantation, and severe or refractory autoimmune disorders. Considering the large number of ex-vivo expanded cells required for these clinical protocols (MSC dose varies from 1 to 4x106 MSC/kg patient per infusion), we evaluated the Quantum® device, a GMP-compliant, functionally closed, automated hollow fiber bioreactor system and compared it with our traditional clinical culture system in flasks.

Methods: Primary and pre-enriched MSC expansions were simultaneously conducted in both culture systems and evaluated in terms of expansion rates and compliance with quality specifications and ISCT-release criteria. Due to practical considerations, most of the experiments conducted in the bioreactor (P1 and P2 expansions) used thawed MSC. These were compared with both fresh and thawed MSC expansions in flasks.

Results: The Quantum® device reproducibly produced therapeutic MSC doses that fulfill ISCT-release criteria, are sterile, devoid of mycoplasma and endotoxin, have normal karyotypes and demonstrate immunosuppressive and differentiation capacities in vitro. Cells also grew faster in the bioreactor than in flasks during passage P1 (doubling time 40 compared to 56 hours in flasks) and P2 expansions but not during the primary expansion phase (P0). Seeding 20x106 thawed P2-preselected cells on the device allowed us to harvest 110-276x106 MSC after a 7 day expansion; seeding 50x106 cells resulted in 291-334x106 MSC harvested.

Conclusion: In conclusion, the Quantum® device is an excellent system to produce a clinical dose of MSC but cost-effectiveness varies as a function of the manufacturing strategy in place. For our particular situation, the use of the Quantum device didn’t result in a cost saving solution.

Keywords: Bioreactor; Clinical-grade; GMP; MSC; Mesenchymal stem cells; Quantum®

Abbreviations: GMP: Good Manufacturing Practice; BM: Bone Marrow; HSC: Hematopoietic Stem Cells; MSC: Mesenchymal Stem/Stromal Cells; HCT: Hematopoietic Cell Transplantation; NK: Natural Killer; NOD/SCID: Non-Obese Diabetic/Severe Combined Immunodeficient mouse; aGVHD: acute Graft Versus Host Disease; LTCG: Laboratory of Cell and Gene Therapy; EBMT: European group for Blood and Marrow Transplantation; CBT: Cord Blood Transplantation; ATMP: Advanced Therapeutic Medicinal Product; PBS: Phosphate-Buffer Saline; HAS: Human Serum Albumin; DMSO: Dimethylsulfoxide; IC: Intracapillary; DMEM: Dulbecco’s Modified Eagles Medium; DT: doubling time; FBS: Fetal bovine serum; NEAA: Non Essential Amin Acid; β-ME: β-mercaptoethanol; PBMC: Peripheral Blood Mononuclear Cells; MNC: Mononuclear cells; hESC: Human Embryonic Stem Cells; FCS: Fetal Calf Serum; PL: Platelet Lyse

Introduction

Bone marrow (BM) contains two different types of stem cell populations, hematopoietic stem cells (HSC) and non-hematopoietic cells; among the latter, mesenchymal stem cells (MSC) provide an appropriate microenvironment to HSC. MSC are multipotent progenitors capable of differentiating into a number of cell lineages, including bone, cartilage, tendon, muscle or adipose tissue [1-3]. Given their multipotentiality, MSC may be considered a powerful resource for tissue repair and gene therapy.

In recent years, further interest in MSC has been raised by the observation that they exhibit profound immunosuppressive abilities in vitro and in vivo. MSC are weakly immunogenic in humans, even when infused after allogeneic HCT [4,5]. In vitro, MSC support hematopoiesis and inhibit T-cell proliferation [6], NK cell cytotoxicity [7], and dendritic cell differentiation [8,9]. In animal models, co-infusion of MSC have been shown to facilitate engraftment of human cord blood CD34+ cells in non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice [10], to prolong skin allograft survival in baboons [11], and to prevent aGVHD in some mice models [12] as well as in...
a xenogeneic (human into NOD/SCID mice) model of GVHD [13], perhaps by promoting the generation of regulatory T cells [12,14].

In addition, phase II studies in humans have demonstrated that MSC infusions were safe [15-17], and might accelerate lymphocyte recovery and prevent graft failure after haploidentical HCT [18]. Further, MSC infusions have also shown promising efficacy in patients with steroid-refractory aGVHD [19], although a recent industry-sponsored trial failed to show improvement of survival by MSC in that setting [20].

Although MSC are present in low numbers in the BM (0.01% to 0.001% depending on age), they can be easily isolated and when exploiting their adhesive property are capable of proliferation and expansion in vitro.

In the Laboratory of Cell and Gene Therapy (LTCG, CHU of Liège), we started in late 2006 a “MSC bank” based on clinical-grade expansion of MSC from BM samples obtained from healthy volunteer donors. Cells are produced according to the European Group for Blood and Marrow Transplantation (EBMT) consortium recommendations for defining common procedures for MSC isolation and expansion, as well as common release criteria, enabling multicenter trials with comparable MSC products [19]. Indeed, because MSC are believed to act mainly by secreting soluble factors, MSC preparation (MSC origin, culture media, type of serum supplementation, and extent of ex vivo expansion) may have a very significant impact on their ability to produce specific soluble factors.

Our first clinical protocol tested the safety and preliminary efficacy of MSC to prevent graft rejection and GVHD after allogeneic hematopoietic cell transplantation (HCT) with nonmyeloablative conditioning [21]. We are currently involved in 6 clinical trials of MSC infusion in different settings including HSC transplantation (HCT) with myeloablative or non-myeloablative conditioning, cord blood transplantation (CBT), solid organ transplantation and severe or refractory autoimmune disorders such as Crohn’s disease. According to each protocol, the MSC dose varies from 1 to 4x10^6 MSC/kg patients per infusion.

The large numbers of ex-vivo expanded cells that are required in these clinical cell therapy protocols make standard culture conditions difficult, resulting in the need for extensive personnel and facility resources, and the potential for contamination. Indeed, large scale cultures in T-flasks are difficult to manage and very time-consuming.

For these reasons, we decided to evaluate the Quantum® device from Terumo BCT. This is a robust, functionally closed, automated hollow fiber bioreactor system designed to reproducibly grow both adherent and suspension cells in either GMP or research laboratory environments.

The aim of the present study was to compare our “traditional” T-Flask clinical-grade MSC expansion process with expansion in the Quantum® device. All the release criteria for clinical-grade MSC production were evaluated including: microbiological contamination (sterility, mycoplasma and endotoxin), morphology, viability, phenotype, karyotype, immunosuppressive properties and differentiation potential. Additionally, proliferation rates and production rates at harvest were also compared.

Materials and Methods

Donors

The study was approved by the human and animal Ethics Committees of the University of Liege. Written informed consent was obtained from all bone marrow donors in accordance with the Declaration of Helsinki. Donor eligibility was fully evaluated as per standard procedures.

MSC traditional clinical-grade culture process

Bone marrow (BM) cells were obtained by BM aspirates drawn from the iliac crest of adult volunteers. MSC expansion cultures were performed as described by other groups of investigators [19]. Briefly, BM (30-50 mL) was collected under local anesthesia in sterile conditions, and put in sterile heparin-containing syringes. Mononuclear BM cells were isolated by Ficoll centrifugation (GE Healthcare-Amersham Biosciences AB, Upsala, Sweden), seeded in sterile tissue culture flasks (BD Falcon, Bedford, MA), and cultured in Dulbecco’s Modified Eagles Medium-Low Glucose (DMEM, Invitrogen, Merelbeke, Belgium) with glutamax supplemented with 10% irradiated fetal bovine serum (HyClone-Perbio Science, Merelbeke, Belgium) and antibiotics (penicillin/streptomycin, Lonza Bio Science, Verviers, Belgium). Cultures were maintained at 37°C in humidified atmosphere containing 5% CO2 for a total of about 4 weeks. The medium was replaced twice a week and, after approximately 2 weeks, the cultures were near confluence (>70%). Cells were then detached by treatment with 0.05% trypsin-EDTA (Invitrogen, Merelbeke, Belgium) and replated (first passage) at a lower density to allow further expansion. A second passage was performed one week later; when the cells reached again confluence (>70%). After 2 fruitful passages (generally 4 weeks of culture), the cells were harvested, washed, and resuspended using phosphate-buffered saline (PBS)-EDTA (Miltenyi Biotec, Utrecht, The Netherlands) and Human Serum Albumin (HSA; CDF-CAF, Bruxelles, Belgium). MSC were then frozen in a medium containing 70% PBS, 20% HSA, and 10% DMSO (WAK-Chemie, Steinbach, Germany) by standard techniques.

The following analyses were performed as quality controls for each MSC expansion culture: nucleated cell count on a manual cell counter, flow cytometry analysis with determination of the % cells (on total cells) positive for CD73, CD90, and CD105, and negative for HLA-DR, CD31, CD80, CD14, CD45, CD3, and CD34; cell viability by trypan blue exclusion; microbiology testing, including standard virology, bacterial culture, and search for mycoplasma; endotoxin detection by the limulus test; and cytogenetics. Further, MSC differentiation into adipocytes, osteocytes, and chondrocytes [3] as well as inhibitory effects of MSC on T-cell proliferation in MLR assays were evaluated after some MSC expansions.

MSC Quantum® automated expansion system

The Quantum bioreactor culture system comprises a synthetic hollow fiber bioreactor that is part of a sterile closed-loop circuit for media and gas exchange. The bioreactor and fluid circuit are a single-use disposable set that is mounted onto the Quantum system unit. The bioreactor itself is formed by ~11,500 hollow fibers with a total intracapillary (IC) surface area of 2.1 m². Typical culture manipulations (e.g., cell seeding, media exchanges, trypsinization, cell harvest, etc.) are managed by the computer-controlled system using pumps and automated valves, which direct fluid through the disposable set and exchanges gas with the media. The functionally closed nature of the disposable set is maintained through the sterile docking of bags used for all fluids; these bag connections/disconnections all utilize sterile connection technology. Gas control in the system is managed using a hollow fiber oxygenator. Gas is supplied from a user-provided premixed gas tank. By choosing a tank with the desired gas mixture, the user can...
expand cells at their optimal gas concentration. The IC membrane of
the bioreactor is coated with an adhesion promoter (fibronectin) to
allow the attachment of adherent cell populations.

We used the system for the ex vivo expansion of clinical-scale
human MSC. BM or MSC from pre-expanded cells were expanded in
the system with the same media than for traditional T-flasks.

In the Quantum® device process, a single-use disposable set is
mounted onto the Quantum® system unit for each step of the culture
(P0, P1 and P2) and needs to be coated overnight with 20x10⁶ mg of human
fibroinectin (BD Biosciences, Germany) to promote cell adhesion.
P2 is generally multi-step because, following recommendations of
the manufacturer; each disposable is ideally loaded with 20x10⁶ pre-
selected MSC. As cells are not visible in the hollow fiber, confluence
is estimated according to glucose consumption and lactate generation
by the cells in the system. Fresh complete media is added continuously
to cells and the inlet rate is adjusted as required by the rate of glucose
consumption and lactate generation.

Doubling time estimation

Doubling time (DT) was calculated according to the formula

\[
DT = \frac{t \times \log(2)}{\log(\text{number of cells harvested/number of cells inoculated})}
\]

where, \(t\) is the time in hours between initial plating and harvest for
the respective passage.

**Phenotypic characterization of MSC**

Flow cytometry analysis was performed for each MSC product
harvested after expansion in the Quantum® device or in T-Flasks and the
% of cells positive for CD73, CD105, CD90 and negative for HLA-DR,
CD14, CD45, CD3 and CD34 was determined on total cells. Phenotype
analysis was performed in the laboratory of immunohematology of the
hospital (Prof. Gothot).

**Mesenchymal stem cell differentiation assays**

Fat, bone and cartilage differentiation assays were carried out as
described by Pittenger et al. [3] and revealed by staining with oil red O,
alizarin red and toluidine blue, respectively.

**MSC immunosuppression assays**

Ten thousand MSC were plated in triplicates in round-bottom 96-
well plates (Becton Dickinson) in a total volume of 100 μl of RPMI 1640
medium supplemented with 10% FBS, 100 U/ml penicillin, 100 mg/ml
streptomycin, L-glutamine (2 mM) all from Lonza, sodium pyruvate
(100 mM), non-essential amino acid (NEAA) (100 mM) and 5x10⁻⁵ M
β-mercaptoethanol (β-ME) all from Gibco, Merelbeek, Belgium. After
4 hour incubation, MSC were irradiated at 25 Gy using a 137 Cs source
by the cells in the system. Fresh complete media is added continuously
to cells and the inlet rate is adjusted as required by the rate of glucose
consumption and lactate generation.

**Phenotypic characterization of MSC**

Flow cytometry analysis was performed for each MSC product
harvested after expansion in the Quantum® device or in T-Flasks and the
% of cells positive for CD73, CD105, CD90 and negative for HLA-DR,
CD14, CD45, CD3 and CD34 was determined on total cells. Phenotype
analysis was performed in the laboratory of immunohematology of the
hospital (Prof. Gothot).

**Mesenchymal stem cell differentiation assays**

Fat, bone and cartilage differentiation assays were carried out as
described by Pittenger et al. [3] and revealed by staining with oil red O,
alizarin red and toluidine blue, respectively.

**MSC immunosuppression assays**

Ten thousand MSC were plated in triplicates in round-bottom 96-
well plates (Becton Dickinson) in a total volume of 100 μl of RPMI 1640
medium supplemented with 10% FBS, 100 U/ml penicillin, 100 mg/ml
streptomycin, L-glutamine (2 mM) all from Lonza, sodium pyruvate
(100 mM), non-essential amino acid (NEAA) (100 mM) and 5x10⁻⁵ M
β-mercaptoethanol (β-ME) all from Gibco, Merelbeek, Belgium. After
4 hour incubation, MSC were irradiated at 25 Gy using a 137 Cs source
(a GammaCell 40, Nordion, Ontario, Canada).

Allogeneic human peripheral mononuclear cells (PBMC) were
isolated from blood by Ficoll Paque Plus® (a GammaCell 40, Nordion, Ontario, Canada).

The percentage of cells in the different phases of the cell cycle was
determined with the Macsquant Software (Miltenyi) or the Modlit
Software (Becton Dickinson). The effect of MSC on PBMC stimulation
responses was calculated as percentage suppression compared with the
proliferative response in the positive control without MSC (± standard
deviation of the mean). The positive control was set to 0% suppression.

**Cytogenetics**

Karyotyping was realized at the Department of Cytogenetics of the
University Hospital of Liège by the Q-bandning technique and analyzed
with Cytovision® software.

**Microbiology testing**

MSC sterility was assessed by bacterial culture (aerobic, anaerobic
and fungal culture with Bactalert®, Organon Teknika Benelux),
detection of mycoplasma (luminometry, Mycoalert®, Lonza Bio
Science, Verviers, Belgium) and endotoxin detection (Limulus test).

**Lactate and glucose analysis**

Lactate concentration in cell culture supernatant was measured using
the Lactate Pro Blood Lactate Test Meter (Arkay Inc., Amstelveen, The
Netherlands) following the manufacturer’s instructions. The Lactate
Pro Test Strip (Arkay) has a measuring range of 0.8–23.3 mmol/L
and conforms to Directive 98/79/EC. Glucose concentration in cell
culture supernatants was analyzed using the Contour Blood Glucose
Monitoring System (Bayer Vital GmbH, Leverkusen, Germany) which
has a measuring range of 10-600 mg/dL and was used according to the
manufacturer’s instructions.

**Statistical analyses**

Cell population doubling times in the various MSC culture
conditions (Flask fresh cells, Flask thawed cells, Quantum thawed cells
20 (loaded at 20x10⁶ cells/device), Quantum thawed cells 50 (loaded
at 50x10⁶ cells/device)) were compared using Mann-Whitney tests.
Statistical analyses were performed with the GraphPad® Prism 5.00
Software (La Jolla, CA).

**Results**

**MSC culture in Quantum® or flasks: fresh bone marrow**

A fresh BM sample was divided in two parts: 25 ml were loaded on
the Quantum® device while 25 ml were submitted to Ficoll isolation
of mononuclear cells (MNC). MNC were divided in two parts: first
part of the cells was seeded in flasks according to our traditional
culture process and the second part of the cells was loaded on a second
Quantum® device (Figure 1). After 14 days, cells were harvested. As
shown in Figure 1, we were able to obtain cells in the Quantum® device
only with crude bone marrow but not with post-Ficoll MNC. A total
of 12.6x10⁶ cells were harvested from the Quantum® device (PIQ cells,
corresponding to 25 ml BM) and 9.8x10⁶ cells were obtained in flasks
from MNC (PIF cells, corresponding to 12.6 ml BM) (Table 1).

As we only had two devices available to proceed to all our
experiments (these were lent by Terumo BCT for evaluation), we had
to freeze and thaw cells between two culture steps (or one machine only
could be used each time). Indeed, the disposable needs to be coated
overnight before loading of the cells (fresh cells, blue boxes, and thawed
cells, green boxes, Figure 1).

P1 Quantum cells (PIQ cells) were thus frozen and then thawed
before being seeded in a new disposable while P1 flasks cells (PIF cells)
were freshly replated at a lower density in flasks (Figure 1). After 7 days, cells were harvested from both culture systems. Cells grew faster in the Quantum® device with a doubling time (DT) of 40 hours (154x10^6 harvested cells from 8.2x10^6 seeded cells, P2Q cells) compared to 56 hours in flasks (76x10^6 cells harvested from 9.7x10^6 seeded cells, P2F cells) (Table 1).

P2Q cells were then frozen in aliquots while P2F cells were freshly replated. Three separate experiments were initiated in Quantum each with 20x10^6 thawed P2Q cells as recommended by Terumo BCT (Figure 1). Cells were allowed to grow 7 days before harvest. Between 110 and 172x10^6 cells were obtained in these 3 runs (DT ranging from 54 to 68 hours). Doubling time in flasks was 64 hours (Table 1). When thawed cells from the same aliquots (P2Q) are seeded in parallel in flasks and in the Quantum® device, cells grow 2 to 4 times faster in Quantum® than in flask (data not shown).

Cell viabilities throughout the whole process were excellent ranging from 89 to 100% (Table 1).

MSC were also tested for quality controls at harvest after P1 and P2 expansions. Sterility, mycoplasma, endotoxin detection,
and karyotyping were performed. All the MSC populations (P3Q and P3F) satisfied to release criteria as they were sterile devoided of mycoplasma and endotoxin and no abnormal cell clone was detected. It wasn’t possible to obtain a karyotype for all cell populations due to low numbers of mitoses in some cases. MSC phenotypes (Table 2) also satisfied to the ISCT release criteria (> 95% of CD90, CD105, CD73 expression and <2% CD14, CD34, CD45 and <1% CD3 expression) [22].

In conclusion for this first set of experiments, the Quantum® device seems to allow higher proliferation rates than flasks except for primary cultures (P0 expansions) and MSC produced with the device satisfy to the usual release criteria of MSC.

### P2 Quantum® or flask expansion: P2 flask thawed MSC (20x10^6 cells)

To test the reproducibility of the device and compare post-thawed MSC expansion between both methods, 3 separate identical bags containing frozen P2 flask MSC were thawed and 20x10^6 cells (P2FT cells) were loaded on the Quantum® device while the remaining cells were seeded in flasks (Figure 2). Cells were allowed to grow for 7 to 9

| Antigen | Specification | P1 expansion | P2 expansion (3) |
|---------|--------------|--------------|-----------------|
|         |              | P2Q | P2F | P3Q-1 | P3Q-2 | P3Q-3 | P3F |
| CD105   | >95          | 98  | 98.5 | 98.6  | 98.4  | 98.4  | 99.5 |
| CD90    | >95          | 96.3| 99.6 | 99.7  | 99.7  | 98.5  | 99.8 |
| CD73    | >95          | 99.6| 99.5 | 99.6  | 99.7  | 99.6  | 99.8 |
| CD34    | <2           | <1/10000 | <1/10000 | <1/10000 | <1/10000 | <1/10000 | <1/10000 |
| CD45    | <2           | <1/10000 | <1/10000 | <1/10000 | <1/10000 | <1/10000 | <1/10000 |
| CD14    | <2           | <1/10000 | <1/10000 | <1/10000 | <1/10000 | <1/10000 | <1/10000 |
| HLA-DR  | /            | <1  | <1   | <1    | <1    | <1    | <1   |

**Table 2: Expression (%) of cell-surface antigens of Q-MSC and F-MSC. Results are shown for P2 and P3 MSC expanded in flasks or the Quantum® device (Figure 1).**

**Figure 2:** Comparison between culture processes in the Quantum® device and traditional flasks: MSC culture from thawed P2 MSC expanded from fresh cells (20x10^6 cells/Quantum). After P0 and P1 expansion in flasks from fresh BM, cells were frozen. Three bags containing frozen P2 MSC from flasks from the same donor were thawed and cells were seeded in parallel in flasks (80x10E6 MSC) or Quantum® devices (20x10^6 MSC). Results were also compared with those previously obtained after P2 from fresh cells from the same donor.
Table 5: Results for P2 expansions from P2 thawed MSC in the Quantum® device or traditional flasks. Results were also compared with those previously obtained after P2 from fresh cells from the same donor (Figure 2).

| Expansion step | Days grown | Cell seeded | Cell harvested | Viability | Doubling time (h) | Number of doublings |
|----------------|------------|-------------|----------------|-----------|-------------------|---------------------|
| **P2 Fresh cells** |            |             |                |           |                   |                     |
| Flask          | 7          | 140 E+06 (P2F) | 870 E+06 (P3F) | 95%       | 63                | 2.6                 |
| **P2 Thawed cells** |            |             |                |           |                   |                     |
| Quantum        | 7          | 20 E+06 (P2FT) | 276 E+06 (P3Q-1) | 93%       | 44                | 3.8                 |
| Flask          | 8          | 80 E+06 (P2FT) | 209 E+06 (P3FT-1) | 95%       | 138               | 1.4                 |
| Quantum        | 7          | 20 E+06 (P2FT) | 178 E+06 (P3Q-2) | 97%       | 53                | 3.2                 |
| Flask          | 9          | 80 E+06 (P2FT) | 249 E+06 (P3FT-2) | 95%       | 132               | 1.6                 |
| Quantum        | 7          | 20 E+06 (P2FT) | 170 E+06 (P3Q-3) | 78%       | 54                | 3.1                 |
| Flask          | 8          | 80 E+06 (P2FT) | 161 E+06 (P3FT-3) | 95%       | 190               | 1.0                 |

Table 3: Results of P2 expansion from P2 thawed MSC in the Quantum® device or traditional flasks. Results were also compared with those obtained after P2 from fresh cells from the same donor (Figure 2).

| Antigen | Specification | Fresh cells | Thawed cells |
|---------|---------------|-------------|--------------|
|         |               | P3F         | P3F-1        | P3Q-1        | P3Q-2        | P3Q-3        | P3F-T-1       | P3F-T-2       | P3Q-2        | P3Q-3        | P3F-T-3       | P3Q-3 |
| CD105   | >95           | 99.8        | 99.4         | 99.1         | 99.6         | 99.1         | 99.6         | 99.1         | 99.6         | 99.6         | 99.6           | 99.2 |
| CD90    | >95           | 99.9        | 99.8         | 99.8         | 99.8         | 99.8         | 99.8         | 99.8         | 99.8         | 99.8         | 99.8           | 99.8 |
| CD73    | >95           | 99.4        | 99.3         | 99.6         | 99.2         | 99.2         | 99.2         | 99.2         | 99.2         | 99.2         | 99.2           | 99.6 |
| CD34    | <2            | <1/10000    | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000       | <1/10000 |
| CD45    | <2            | <1/10000    | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000       | <1/10000 |
| CD3     | <1            | <1/10000    | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000       | <1/10000 |
| CD14    | <2            | <1/10000    | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000     | <1/10000       | <1/10000 |
|          |               |             |             |             |             |             |             |             |             |             |               |       |
|          | HLA-DR        |             |             |             |             |             |             |             |             |             |               |       |

Table 4: Expression (%) of cell-surface antigens of Q-MSC and F-MSC. Results are shown for MSC processed freshly in traditional flasks (F) and for MSC processed after a freezing/thawing step at P2 and replated in the Quantum® device (P3Q) or in flasks (P3F) (Figure 2).

Table 5: Results for P2 expansions from P2 thawed MSC in the Quantum® device and traditional flasks. Results were also compared with those previously obtained after P2 from fresh cells from the two same donors (Figure 3).

P3Q cells were harvested after 7 days while 8 or 9 days were necessary before harvesting P3FT cells. Results were also compared with those previously obtained with fresh cells from the same donor (7 day expansion; P3F cells) (Figure 2 and Table 3). As already observed, doubling times were shorter in Quantum® device (P3Q) or in flasks (P3F) (Figure 2).

P3Q cells were harvested and after 7 or 8 days while P3F cells needed to proliferate 8-10 days before harvest (7 days for fresh cells). For each of the Quantum® runs, we obtained between 291x10^6 and 334x10^6 MSC, which corresponds to 2 or 3 MSC infusions for a patient. DT ranged from 65 to 75 hours for Quantum® cells (P3Q-1A, P3Q-1B and P3Q2 cells), 170 to 294 hours for flasks with frozen cells (P3FT-1A and P3FT-1B cells) and between 73 and 98 hours for fresh cells (P3F1 and P3F2 cells, Table 5). Proliferation was thus higher in Quantum® than in flasks even if we consider fresh cells. Viabilities were very good, ranging from 82 to 95%.

In conclusion, it was possible to increase the number of harvested cells when we loaded onto the Quantum® device more than the initially recommended number of cells (50x10^6 instead of 20x10^6) without impairing compliance to all release criteria (Tables 4 and 6), without clotting and keeping interesting harvest rates.

When we tried to further increase the number of loaded cells to 80x10^6 cells, harvested cells were of poor quality, with aggregates and debris (data not shown).

Comparison between MSC doubling time in different conditions

We compared cell population doubling times in the various culture conditions. Doubling times in flasks were 75 ± 16 hours with fresh cells vs. 185 ± 65 hours with thawed cells (p=0.0159). Doubling...
### Table 6: Expression (%) of cell-surface antigens of Q-MSC and F-MSC. Results are shown for MSC processed freshly in traditional flasks (F) and for MSC processed after a freezing/thawing step at P2 and replated in the Quantum® device (P3Q) or in flasks (P3F) (Figure 3).

| Antigen | Specification | Donor 1 | Donor 2 |
|---------|---------------|---------|---------|
|         | Fresh         | Thawed  | Fresh   | Thawed  |
|         | P3F-1         | P3FT-1A | P3Q-1A  | P3Q-1B  |
| CD105   | >95           | 99.7    | 99.9    | 99.5    | 98      |
| CD90    | >95           | 99.4    | 99.8    | 99.8    | 99.9    |
| CD73    | >95           | 99.8    | 99.7    | 99.8    | 99.5    |
| CD34    | <2            | <1/10000| <1/10000| <1/10000| <1/10000|
| CD45    | <2            | <1/10000| <1/10000| <1/10000| <1/10000|
| CD3     | <1            | <1/10000| <1/10000| <1/10000| <1/10000|
| CD14    | <2            | <1/10000| <1/10000| <1/10000| <1/10000|
| HLA-DR  | /             | <1      | <1      | <1      | <1      |

### Table 7: Quantum® device and T-flask MSC manufacturing requirements (P2 expansion step). Comparison between Quantum® and T-flask (fresh or thawed cells) manufacturing needs considering a P2 expansion step leading to a 300x10⁶ MSC harvest.

| 300x10⁶ harvested cells | Quantum (thawed cells) | Flask (fresh cells) | Flask (thawed cells) |
|-------------------------|------------------------|---------------------|----------------------|
| Loaded cells            | 50x10⁶                 | 62x10⁶              | 138x10⁶              |
| Days in culture         | 7                      | 7                   | 8                    |
| Disposables (kits, bags, flasks) | 1 disposable kit+bags | 88 flasks          | 198 flasks           |
| Medium consumption      | 7,840 mL               | 5,040 mL            | 11,200 mL           |
| Working time / run (hours) | 8                    | 12                  | 21                   |
| Working time/harvest+freezing (hours) | 3            | 7                   | 15                   |

**Figure 3:** Comparison between culture processes in the Quantum® device and traditional flasks. MSC culture from thawed P2 MSC expanded from fresh cells (50x10⁶ cells/Quantum). After P0 and P1 expansion in flasks from fresh BM, cells were frozen. Three bags containing frozen P2 MSC from P2 flasks from two different donors were thawed and cells were seeded in parallel in flasks (80x10⁶) or Quantum® devices (50x10⁶). Results were also compared with those previously obtained after P2 from fresh cells from the same donors.
times in Quantum devices were 55 ± 8 hours with 20x10^6 thawed cells vs. 70 ± 5 hours with 50x10^6 thawed cells (p=0.0489). Thawed cells cultured in Quantum devices grew faster than thawed cells (p=0.0043 and p=0.0357, respectively when 20 or 50x10^6 cells were loaded) or even fresh cells (p=0.0381 with 20x10^6 cells, but NS with 50x10^6 cells) cultured in flasks.

**Differentiation**

Three samples of P3Q cells and P3F cells were subjected to differentiation into osteoblastic, adipocytic and chondrocytic lineages. P3Q cells and P3F cells differentiated equally well towards the 3 lineages (data not shown).

**Immunosuppressive properties**

Immunosuppressive properties of MSC were also assessed in three samples of P3Q cells and P3F cells. As shown in a representative experiment in Figure 4, P3Q and P3F cells displayed similar immunosuppressive properties.

Indeed, proliferation of stimulated PBMC was similarly reduced by P3Q or P3F cells (Figure 4A and B), and these results are similar to those obtained with fresh cells from the same donor indicating than the freezing/thawing step didn’t impair MSC intrinsic immune properties (Figure 4C and D).

**Discussion**

In recent years, interest in MSCs has been raised by the observation that they exhibit profound immunosuppressive abilities *in vitro* and *in vivo*. These are thus now evaluated in numerous clinical studies particularly in the transplantation setting [23].

---

**Figure 4:** Inhibition of PBMC proliferation by third party MSC: comparison between Q-MSC and F-MSC. PBMC (100,000 or 50,000) were stimulated (S-PBMC) with anti-αCD3/CD28 microbeads during 4 days with or without irradiated (25 Gy) MSC (10/1 or 5/1 PBMC/MSC ratios) added at the beginning of the culture. Proliferation was assessed by analysis of the cell cycle by flow cytometry. One representative experiment is shown. Result are expressed as the percentage of cells present in S+G2M phases (A) and as the percentage of inhibition compared to the stimulated PBMC condition alone (B). Similar results with fresh cells (from flasks) from the same donor are shown in (C) and (D).
The procedure used to prepare MSC for clinical applications are based on enrichment of MSC present in bone marrow mononuclear cells by plastic adherence, followed by ex vivo expansion in selected serum-containing media [24]. As traditional culture in T-flasks is quite time-consuming and bulky, we decided to evaluate a new culture system in the Quantum® bioreactor from Terumo BCT, notably developed for ex-vivo expansion of clinical scale human MSC. Until now, few studies have been initiated to evaluate the system. Roberts et al. demonstrated that human embryonic stem cells (hESC) culture can be scaled up through the use of the bioreactor [25] and two recently published studies evaluated the Quantum® device to isolate and expand BM-MSC in FCS or platelet lysate (PL)-enriched media in two-step processes [26,27].

In the present study, we evaluated the Quantum® bioreactor system according to our clinical process requirements and results were compared with those from cells obtained by our traditional culture system in flasks.

Our first goal was to investigate whether it was possible to manage the whole culture process from a bone marrow collection (P0) to final harvest of MSC (P3) with the system. This is indeed feasible and the Quantum® device seems to allow higher proliferation rates than flasks in our conditions (excepted for primary cultures P0 expansions). We harvested between 110 and 172x10⁶ cells after each P2 expansions (3 separate runs, 20x10⁶ loaded cells each).

In a second set of 3 separate experiments, we evaluated the reproducibility of the method and the feasibility of expanding P2-thawed preselected cells (initially obtained in flasks). P2 expansion represents the last step of MSC culture leading to harvest of clinically usable cells. Each run with the Quantum® device allowed us to harvest from 170x10⁶ to 276x10⁶ cells, which represents one or two MSC infusions for one patient.

With these experiments, we have demonstrated that despite some differences between the two culture systems, it is possible to produce “clinical grade” MSC satisfying to all release criteria with the Quantum® device. Indeed, both Flask- and Quantum®-MSC satisfied to all the ISCT-release criteria. Q-MSC expressed >95% CD73, CD90 and CD105 receptors and lacked expression of hematopoietic markers (<2%), such as CD34, CD45 and HLA-DR and blood cell lineage-specific antigens, such as CD14 (<2%) and CD3 (<1%). Immunosuppressive properties and differentiation into fat, bone and cartilage were also similar. Cytogenetic analyses were normal, in agreement with the recently published study of Jones et al. [28].

Rojewski et al. showed that the Quantum® system reliably produces a therapeutic cell dose that fulfills MSC criteria in a two-step process. Our results are in accordance if we compare expansion of 20x10⁶ pre-selected cells. Similar DT (around 40 hours) and cellular outputs (around 150 x10⁶ MSC) were obtained in both studies. However, when they compared growth rates between traditional flask culture and the bioreactor, results were in favor of flask culture. In our study, cells grew faster in the bioreactor than in flasks. This is probably partially due to differences in flask seeding density. In our experiments, we work with the EBMT-recommended seeding density of 4,000 cells/cm². This is indeed much more than the seeding density in the bioreactor (a density of 950 cells/cm² is obtained when loading 20x10⁶ cells in a disposable of 2.1 m²). Moreover, Nold et al., who also worked at a higher density in flasks (5,000 cells/cm²) than in the Quantum® bioreactor, also reported similar or better DT in the Quantum® system than in flasks [27].

Loading 15-20x10⁶ cells per disposable is the most common seeding strategy for the Quantum system. This means that for a P2 expansion step, it is necessary to freeze cells in adequate aliquots before thawing each one for a new expansion run unless several machines are available.

In order to limit freezing/thawing steps, we tried in a third set of 3 separate experiments to increase the number of loaded cells to 50x10⁶ P2-thawed flask preselected cells. For each run, we harvested between 291 and 334x10⁶ MSC, which corresponds to 2 or 3 MSC infusions for one patient. Again, cells fulfilled MSC release criteria. Thus, it was possible to increase cellular output by increasing the number of loaded cells. However, further increasing initial cell loading to 80x10⁶ was not possible as it resulted in aggregation of cells with poor viability.

We had two Quantum devices available for our experiments and the procedure of the time required an overnight coating with fibronectin before loading cells. Therefore, all runs in the bioreactor were performed with frozen/thawed cells (except the P0 to P1 step). This was a considerable disadvantage as thawed cells proliferate more slowly than fresh cells. This suggests that if we had additional devices to work with fresh cells, we should probably improve cell output in the bioreactors. Rojewski et al. also addressed the question of loading cryopreserved versus fresh cells in the bioreactor and they observed, in agreement with our results, higher doubling time for cryopreserved cells than for freshly pre-expanded MSC. Interestingly, they didn’t notice any difference when comparing cytokine level profile of thawed compared to fresh cells.

As our banking objective is to produce a maximum amount of MSC from a single BM sample without intermediate freezing steps, we are confronted with two major hurdles before adopting clinical production of MSC in the Quantum® bioreactor, i.e. overnight coating of the disposables and the limited number of cells that can be loaded on the device. To circumvent these limitations, we have actually two possibilities. First, we could scale up by working with additional devices (for example a minimum of 4 devices would be necessary for a 200x10⁶ P2 expansion) or we could freeze cell aliquots at each passage and thaw them later for further expansion in separate runs. However, these supplemental steps are time-consuming and also induce additional costs. Indeed, some preparative tasks such as bag filling and installation of the disposable for example need to be repeated and a new disposable is required for each run. Table 7 compares MSC manufacturing requirements between the Quantum® bioreactor and T-flasks (fresh or thawed cells) considering one P2 expansion step leading to a 300x10⁶ MSC harvest. Main disposables (kit, bags, T-flasks), media, reagents and working time were considered. In our strategy, costs are still 4 to 8 times higher using the bioreactor as compared to T-flasks (mainly due to the cost of the disposable kit) for expansion of fresh or thawed cells, respectively, despite a reduced working time with the Quantum® device (essentially at the harvesting step). The purpose of our study was to compare the process currently used for our clinical grade MSC production with a fully closed bioreactor system. However, an interesting option could also be to compare the bioreactor with the Cellfactories® (Corning) or Cellfactories® (Nunc) widely used by others. These are also open systems but probably allow managing more cells in a shorter time period [21].

In conclusion, the major advantages of the bioreactor are that (1) cells can grow better in the Quantum® than in flasks, (2) working time is shorter especially at the final harvest step, and (3) all the feeding tasks are done automatically. This system can thus allow production of MSC according to good manufacturing practice (GMP), but we have encountered limitations in the attempt to directly translate our
established manufacturing strategy. For our particular situation, the use of the Quantum device didn’t result in a cost-saving solution.

Thus to adopt the system in our facility, increasing the capacity of the bioreactor and thus cell output is necessary so that the cost balance is reversed. Such new developments have just been evaluated at TerumoBCT. First, a new seeding protocol has been developed for the device leading to an increased harvesting rate. Second, shorter coating of the disposable (4 hours instead of overnight) is now feasible. This will probably allow laboratories to work with fewer devices and to avoid freezing/thawing steps, thereby increasing proliferation rates and cell recovery.

Our study was designed to compare MSC cultures in T-flasks and in a bioreactor system and to optimize cultures in the Quantum Device®, for clinical purposes. Hence, cultures were stopped after passage 2 and quality controls were those usually recommended for clinical grade MSC expansion products [19,21,24,29]. However, for research purposes, it would be interesting to evaluate cultures at later passages as published results suggest that late passage MSC are less effective than early passage due to cell senescence [30-32]. MSC characterization could then also be more refined as cells expanded in different in vitro systems may have different in vivo behaviour even if they have comparable phenotypes and differentiation abilities. Quantification of intracellular proteins of interest and measurements of secreted factors (among which SCF, IL-6, SDF-1, TGF-β1, RANTES, βFGF, …) should be interesting for further understanding MSC biology in these various expansion systems.

Acknowledgments

We are very grateful to Sylviane Simar and Amelie Lübcke for their technical assistance. We also thank Mauricette Jamar and Christian Herens for karyotype analysis. The authors are also grateful to Sandra Ormenese and Raafat Stephan from the Imaging and Flow Cytometry Platform of the GIGA for help with cell cycle analyses and Pr. A. Gothot from the Immunohematology Laboratory for MSC phenotypes. We are grateful to Terumo BCT for providing us with bioreactors, disposables and their good advices.

This work has been supported by grants from the Belgian Federal Cancer Plan, the National Fund for Scientific Research (FNRS) and the Belgian Foundation against Cancer.

References

1. Le Blanc K, Ringden O (2005) Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Blood Marrow Transplant 11: 321-334. [PubMed]
2. Jones EA, Kinsey SE, English A, Jones RA, Strasznyski L, et al. (2002) Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum 46: 3349-3360. [PubMed]
3. Pfitzner MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147. [PubMed]
4. Sundin M, Ringden O, Sundberg B, Nava S, Gotherosstrum C, et al. (2007) No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 92: 1208-1215. [PubMed]
5. Sundin M, Barnett AJ, Ringden O, Uzunel M, Lonnies H, et al. (2009) HSCT recipients have specific tolerance to MSC but not to the MSC donor. J Immunother 32: 755-764. [PubMed]
6. Di NM, Carlo-Stella C, Magni M, Milanesi L, Longoni PD, et al. (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99: 3838-3843. [PubMed]
7. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L (2006) Mesenchymal stem cell-based natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107: 1484-1490. [PubMed]
8. Jiang XX, Zhang Y, Lu B, Zhang SX, Wu Y, et al. (2005) Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105: 4120-4126. [PubMed]
9. Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, et al. (2005) Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T+ subsets expressing a regulatory/suppressive phenotype. Haematologica 90: 516-525. [PubMed]
10. Noort WA, Kruisselbrink AB, Ir't Anker PS, Kruger M, van Bezooyen RL, et al. (2002) Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34+ cells in NOD/SCID mice. Exp Hematol 30: 870-876. [PubMed]
11. Bartholomew A, Sturgeon C, Siatokas M, Ferrer K, McIntosh K, et al. (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30: 42-48. [PubMed]
12. Li H, Guo Z, Jiang X, Zhu H, Li X, et al. (2008) Mesenchymal stem cells alter migratory property of T and dendritic cells to delay the development of murine lethal acute graft-versus-host disease. Stem Cells 26: 2531-2541. [PubMed]
13. Tisato V, Naresh K, Girdesstone J, Navarrete C, Dazzi F (2007) Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia 21: 1992-1999. [PubMed]
14. Casiraghi F, Azzolini N, Cassisi P, Imberti B, Morjil M, et al. (2008) Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 181: 3933-3946. [PubMed]
15. Horvitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, et al. (2002) Isolated allogeneic bone marrow-derived mesenchymal cells engrat and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 99: 8932-8937. [PubMed]
16. Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, et al. (2000) Rapid hematopoietic recovery after infusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 18: 307-318. [PubMed]
17. Lazanaus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, et al. (2005) Cotransplantation of MLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 11: 389-398. [PubMed]
18. Ball LM, Bernardo ME, Roefs K, Lankester A, Cometa A, et al. (2007) Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 110: 2764-2767. [PubMed]
19. Le Blanc K, Frassoni F, Balli L, Locatelli F, Roelofs H, et al. (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371: 1579-1586. [PubMed]
20. Allison M (2009) Genzyme backs Osiris, despite Prochymal flop. Nat Biotechnol 27: 966-967. [PubMed]
21. Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, et al. (2010) Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 16: 838-847. [PubMed]
22. Horwitz EM, Le BK, Dominici M, Mueller I, Slaper-Cortenbach I, et al. (2005) Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 7: 393-395. [PubMed]
23. Baron F, Storb R (2012) Mesenchymal stromal cells: a new tool against graft-versus-host disease? Biol Blood Marrow Transplant 18: 822-840. [PubMed]
24. Dominici M, Le BK, Mueller I, Slaper-Cortenbach I, Marini F, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317.
25. Roberts I, Balia S, Rice RB, Janssens ME, Nguyen K, et al. (2012) Scale-up of human embryonic stem cell culture using a hollow fibre bioreactor. Biotechnol Lett 34: 2307-2315. [PubMed]
26. Roejewski MT, Fekete N, Balia S, Sakanee K, Kurst D, et al. (2012) GMP-compliant isolation and expansion of bone marrow-derived MSCs in the closed, automated device Quantum Cell Expansion system. Cell Transplant 22: 1981-2000. [PubMed]
27. Nold P, Brendel C, Neubauer A, Bein G, Hackstein H (2013) Good manufacturing practice-compliant animal-free expansion of human bone marrow derived mesenchymal stroma cells in a closed hollow-fiber-based bioreactor. Biochem Biophys Res Commun 430: 325-330.

28. Jones M, Varella-García M, Skokan M, Bryce S, Schowinsky J, et al. (2013) Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System. Cytotherapy 15: 1323-1339. [PubMed]

29. Sharma RR, Pollock K, Hubel A, McKenna D (2014) Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion 54: 1418-1437. [PubMed]

30. Bork S, Pfister S, Witt H, Horn P, Korn B, et al. (2010) DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells. Aging Cell 9: 54-63. [PubMed]

31. Cakouros D, Isermann S, Cooper L, Zannettino A, Anderson P, et al. (2012) Twist-1 induces Ezh2 recruitment regulating histone methylation along the Ink4A/Arf locus in mesenchymal stem cells. Mol Cell Biol 32: 1433-1441. [PubMed]

32. Digirolamo CM, Stokes D, Cotter D, Phinney DG, Class R, et al. (1999) Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol 107: 272-281. [PubMed]